Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study. Headache Med [Internet]. 2024 Sep. 30 [cited 2026 Jan. 22];15(3):170-4. Available from: https://headachemedicine.com.br/hm/article/view/1308